Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- an article about an “appeal seeking to revive a patent covering [a] Parkinson’s disease drug Neupro”; and
- another article discussing how four law professors argue the “Supreme Court should weigh in on whether artificial intelligence systems can produce patentable inventions.”
Blake Brittain authored an article for Reuters about an “appeal seeking to revive a patent covering [a] Parkinson’s disease drug Neupro. The article discusses how the appeal failed, “clearing an obstacle for . . . Actavis Laboratories UT Inc. and . . . Mylan Technologies Inc. to sell generic versions of the drug.” Brittain reported that the patent owner “UCB sold over 300 million Euros worth of the drug worldwide last year.”
Skye Witley authored an article discussing how four law professors argue the “Supreme Court should weigh in on whether artificial intelligence systems can produce patentable inventions and reverse a Federal Circuit decision saying they can’t.” Witley reported how “the professors from Harvard, Cornell, and Fordham universities and a Yale University fellow wrote” that the “denial of a patent for computer scientist Stephen Thaler’s AI system will endanger ‘thousands or even tens of thousands’ of AI-related patent filings.” Witley also explained how the professors and fellow argue the decision, “if left standing, threatens US innovation and potentially life-saving inventions.”